Tamoxifen
Tamoxifen is a selective estrogen receptor modulator (SERM) and one of the most widely used endocrine therapies in oncology, particularly for the treatment of hormone receptor-positive (HR+) breast cancer.
Tamoxifen is a selective estrogen receptor modulator (SERM) and one of the most widely used endocrine therapies in oncology, particularly for the treatment of hormone receptor-positive (HR+) breast cancer. It acts by competitively binding to estrogen receptors (ERs), thereby blocking estrogen-driven transcription and inhibiting the proliferation of ER-positive tumor cells. Approved for both early-stage and metastatic breast cancer, tamoxifen is prescribed over extended durations of 5–10 years, often alongside or in sequence with aromatase inhibitors such as letrozole, anastrozole, and exemestane, collectively constituting the standard hormone therapy (HT) armamentarium. Beyond oncology, tamoxifen has been investigated in non-malignant conditions, including Duchenne muscular dystrophy (DMD), where its pleiotropic cellular effects may confer therapeutic benefit independent of its antiestrogenic activity.
The drug's mechanism extends beyond direct ER antagonism: tamoxifen modulates downstream Signaling cascades including the PI3K/Akt signaling pathway, NF-κB Signaling, and Rac1/P-Rex1 GTPase activity, which collectively regulate cell survival, proliferation, and metastatic potential. These multi-pathway interactions underlie both its therapeutic efficacy and the complexity of resistance mechanisms that limit its long-term effectiveness in a significant subset of patients.
Where the papers sit
9 papers from the last 6 months study tamoxifen directly · updated from PubMed 1 Nov 2026
Study type 2 clinical trials · 2 observational · 1 human data · 3 preclinical · 1 unclassified
Themes one subject
Those 9 are all about one subject.
-
Tamoxifen Applications and Outcomes
Clinical work centers on tamoxifen use in breast cancer, including antidepressant co-treatment, ovarian suppression, symptom management, and long-term benefit. Laboratory studies examine endocrine resistance through tumour microenvironment effects, lipid-membrane adaptation, glycation products, and altered viability. Lipid nanoparticles are being explored to improve apoptosis in triple-negative breast cancer. Additional studies investigate tamoxifen in spinal cord repair and other experimental settings, leaving the overall field broad rather than directional.
Papers
The 9 papers from the last 6 months that study tamoxifen directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Tamoxifen Applications and Outcomes (9)
- PMID 42143445
- Concurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real-World Cohort Study. Psycho-oncology · 30 Sept 2026 PMID 42814596
- Tamoxifen Modulates Spinal Cord Injury Repair Via CCL2/CCR2 Axis and its Mechanisms. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 12 Sept 2026 PMID 42730874
- Efficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study. Medwave · 19 Aug 2026 PMID 42617170
- The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial. BMC medicine · 6 Aug 2026 PMID 42557562
- Lipidomic adaptation and membrane physical changes underlie tamoxifen resistance in breast cancer: molecular dynamics simulation study. Physical chemistry chemical physics : PCCP · 5 Aug 2026 PMID 42552972
- Starved of oxygen and fueled by macrophages: Path to progression in RCC. Cancer cell · 13 Jul 2026 PMID 42442342
- Tamoxifen loaded lipid nanoparticles as a novel therapeutic approach enhancing apoptotic cell death in triple negative breast cancer cells. Discover nano · 28 Jun 2026 PMID 42366314
- Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach. JMIR cancer · 26 May 2026 PMID 42190242
By study type
Clinical trials (2)
- The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial. BMC medicine · 6 Aug 2026 PMID 42557562
- Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach. JMIR cancer · 26 May 2026 PMID 42190242
Observational studies and case reports (2)
- Concurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real-World Cohort Study. Psycho-oncology · 30 Sept 2026 PMID 42814596
- Efficacy and safety of goserelin vs. leuprolide in premenopausal breast cancer patients receiving adjuvant endocrine therapy: A retrospective cohort study. Medwave · 19 Aug 2026 PMID 42617170
Human data, design not indexed (1)
- Lipidomic adaptation and membrane physical changes underlie tamoxifen resistance in breast cancer: molecular dynamics simulation study. Physical chemistry chemical physics : PCCP · 5 Aug 2026 PMID 42552972
Preclinical: animal, cell and lab studies (3)
- DYNLT1-TP53BP2 axis drives tamoxifen resistance in breast cancer by activating PI3K/Akt/mTOR signaling. Life sciences · 21 Sept 2026 PMID 42767450
- Tamoxifen Modulates Spinal Cord Injury Repair Via CCL2/CCR2 Axis and its Mechanisms. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 12 Sept 2026 PMID 42730874
- Starved of oxygen and fueled by macrophages: Path to progression in RCC. Cancer cell · 13 Jul 2026 PMID 42442342
Unclassified: not yet indexed with MeSH (1)
- Tamoxifen loaded lipid nanoparticles as a novel therapeutic approach enhancing apoptotic cell death in triple negative breast cancer cells. Discover nano · 28 Jun 2026 PMID 42366314
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-15. Last written: 2026-09-14 by GPT. Drafted by language models from published abstracts; not medical advice.